New research indicates that individuals who come off popular slimming jabs like Mounjaro or Wegovy may regain reduced body mass far faster than those who end conventional diet and exercise programs.
Published data in a major health publication demonstrates that while overweight individuals often shed about a fifth of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users purchasing such drugs should be aware of the risk of quick rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment mass in about one and a half years.
Weighing Therapies
The analysis, which examined 37 of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with other pills.
Scientists emphasize that people who lose weight through lifestyle changes alone generally see a less rapid creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Nutrition scientists suggest the mechanism of the drugs explains the heightened rebound.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels several times higher than normal may cause the body to produce less of its endogenous hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in appetite is unsuppressed, making overeating a significant risk."
A Lifelong Condition?
Health authorities recommend the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the significant potential of weight regain, the therapy should be considered long-term.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the long-term character of obesity," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the jabs describe a intense resurgence of cravings.
"It felt as if a switch activating and I was suddenly starving," said an individual.
This difficulty is exacerbated if individuals have not established permanent lifestyle or habit changes during therapy.
Significant Adoption
Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is higher among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and long-term success relies on ongoing behavioural management.
